Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective

Speciality: Hematology


Speaker:

Prof. Dr. Carsten Schmidt | MA, FEBGH Department of Internal Medicine (Gastroenterology, Metabolic Diseases), Fulda Hospital

Description:

A warm welcome to all the medical professionals in this session, focusing on Ferric Maltol as a New Treatment Option- A Further Discussion on a New Perspective on Iron Deficiency Anemia (IDA). This discussion will build upon previous insights, offering a fresh perspective on how ferric maltol's unique properties are changing the clinical approach to IDA. The key new perspective lies in its ability to circumvent the common limitations of traditional oral iron supplements, particularly in patients with chronic inflammatory conditions.

A major challenge with conventional oral iron salts is their poor absorption and high incidence of gastrointestinal side effects, which is often exacerbated by inflammation. Ferric maltol offers a new paradigm by maintaining a stable and soluble complex of iron (Fe³⁺) and maltol, which prevents the formation of free iron in the gut. This minimizes irritation and oxidative stress, leading to superior gastrointestinal tolerability. This is crucial for patients with conditions like Inflammatory Bowel Disease (IBD), where traditional iron can worsen symptoms.

Therefore, get a comprehensive understanding of this new perspective on IDA management. This session will provide valuable insights into how ferric maltol's unique mechanism translates into better patient outcomes and adherence, particularly for those with a history of intolerance or non-response to conventional oral iron. Absorb the shared knowledge and follow Hidoc for more such indispensable sessions that keep you at the forefront of medical advancements.


See More Webinars @ Hidoc Webinars





Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975

2.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

3.

Interleukin-6 may boost prediction of obesity-related cancers

4.

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

5.

As EGFR internalization is decreased, BUB1 controls EGFR signaling.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot